Systematic review of hepatocellular adenoma in China and other regions

Journal of Gastroenterology and Hepatology (Australia)

Volumn 26, Issue 1, 2011, Pages 28-35

  Lin, Haoming ^b   Van Den Esschert, Jacomina ^a   Liu, Chao ^b   Van Gulik, Thomas M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

Bleeding; Hepatocellular carcinoma; Liver; Liver cell adenoma; Oral contraceptive; Tumor

Indexed keywords

ABDOMINAL PAIN; ACUTE ABDOMEN; ARTIFICIAL EMBOLISM; CANCER INCIDENCE; CANCER MORTALITY; CHINA; CLINICAL FEATURE; EUROPE; HEPATITIS B; HEPATITIS B VIRUS; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; LIVER ADENOMA; LIVER CELL CARCINOMA; NORTH AMERICA; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; SOUTHEAST ASIA; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC);

EID: 78650378866     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06502.x     Document Type: Review

References (26)

1. Edmondson HA, Henderson B, Benton B. Liver-cell adenomas associated with use of oral contraceptives. N. Engl. J. Med. 1976; 294: 470-2.
2. Buhler H, Pirovino M, Akobiantz A et al. Regression of liver cell adenoma. A follow-up study of three consecutive patients after discontinuation of oral contraceptive use. Gastroenterology 1982; 82: 775-82.
3. Rooks JB, Ory HW, Ishak KG et al. Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. JAMA 1979; 242: 644-8.
4. Heinemann LA, Weimann A, Gerken G et al. Modern oral contraceptive use and benign liver tumors: the German Benign Liver Tumor Case-Control Study. Eur. J. Contracept. Reprod. Health Care. 1998; 3: 194-200.
5. Bluteau O, Jeannot E, Bioulac-Sage P et al. Bi-allelic inactivation of TCF1 in hepatic adenomas. Nat. Genet. 2002; 32: 312-15.
6. Frain M, Swart G, Monaci P et al. The liver-specific transcription factor LF-B1 contains a highly diverged homeobox DNA binding domain. Cell 1989; 59: 145-57.
7. Terkivatan T, de Wilt JH, de Man RA et al. Indications and long-term outcome of treatment for benign hepatic tumors: a critical appraisal. Arch. Surg. 2001; 136: 1033-8.
8. Grazioli L, Federle MP, Brancatelli G et al. Hepatic adenomas: imaging and pathologic findings. Radiographics 2001; 21: 877-92.
9. Craig JR, Peters RL, Edmondson HA. Atlas of tumor pathology, second series, fascicle 27: tumor of the liver and intrahepatic bile ducts. In: Craig JR, Peters RL, Edmondson HA, eds. Armed Forces Institute of Pathology. Washington, DC: Armed Forces Institute of Pathology, 1989; 19-41.
10. Espat J, Chamberlain RS, Sklar C et al. Hepatic adenoma associated with recombinant human growth hormone therapy in a patient with Turner's syndrome. Dig. Surg. 2000; 17: 640-3.
11. Hsu CY, Chu CH, Lin SC et al. Concomitant hepatocellular adenoma and adenomatous hyperplasia in a patient without cirrhosis. World J. Gastroenterol. 2003; 9: 627-30.
12. Martin NM, bu Dayyeh BK, Chung RT. Anabolic steroid abuse causing recurrent hepatic adenomas and hemorrhage. World J. Gastroenterol. 2008; 14: 4573-5.
13. Caballes RL, Caballes RA. Multiple hepatocellular adenomas in a patient with a history of oral contraception. Int. J. Gynaecol. Obstet. 1999; 64: 177-80.
14. Barthelmes L, Tait IS. Liver cell adenoma and liver cell adenomatosis. HPB (Oxford) 2005; 7: 186-96.
15. Allmark E. Hepatic adenoma: an unusual cause of abdominal pain. Emerg. Nurse 2007; 15: 18-22.
16. Lizardi-Cervera J, Cuellar-Gamboa L, Motola-Kuba D. Focal nodular hyperplasia and hepatic adenoma: a review. Ann. Hepatol. 2006; 5: 206-11.
17. Shortell CK, Schwartz SI. Hepatic adenoma and focal nodular hyperplasia. Surg. Gynecol. Obstet. 1991; 173: 426-31.
18. Cobey FC, Salem RR. A review of liver masses in pregnancy and a proposed algorithm for their diagnosis and management. Am. J. Surg. 2004; 187: 181-91.
19. Flowers BF, McBurney RP, Vera SR. Ruptured hepatic adenoma. A spectrum of presentation and treatment. Am. Surg. 1990; 56: 380-3.
20. Erdogan D, Busch OR, van Gulik TM et al. Management of spontaneous haemorrhage and rupture of hepatocellular adenomas. A single centre experience. Liver Int. 2006; 26: 433-8.
21. Ault GT, Wren SM, Ralls PW et al. Selective management of hepatic adenomas. Am. Surg. 1996; 62: 825-9.
22. Marini P, Vilgrain V, Belghiti J. Management of spontaneous rupture of liver tumours. Dig. Surg. 2002; 19: 109-13.
23. Erdogan D, van Delden OM, van Gulik TM et al. Selective transcatheter arterial embolization for treatment of bleeding complications or reduction of tumor mass of hepatocellular adenomas. Cardiovasc. Intervent. Radiol. 2007; 30: 1252-8.
24. Tao LC. Oral contraceptive-associated liver cell adenoma and hepatocellular carcinoma. Cytomorphology and mechanism of malignant transformation. Cancer 1991; 68: 341-7.
25. Closset J, Veys I, Peny MO et al. Retrospective analysis of 29 patients surgically treated for hepatocellular adenoma or focal nodular hyperplasia. Hepatogastroenterology 2000; 47: 1382-4.
26. Foster JH, Berman MM. The malignant transformation of liver cell adenomas. Arch. Surg. 1994; 129: 712-17.